Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Negative Health Effects Associated with Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT

  • By

  • Otto Simonsson

  • Melissa Bradley

  • Joshua C. Black

  • Karilynn M. Rockhill

  • Andrew A. Monte

  • Peter S. Hendricks

  • September 29, 2026

Share

  • 1

    The study analyzed health outcomes associated with psilocybin, LSD, MDMA, ibogaine, and 5-MeO-DMT using data from the 2025 National Survey Investigating Hallucinogenic Trends.

  • 2

    Among 1964 adults surveyed, psilocybin had the highest reported use at 3.1%, while ibogaine had the lowest at 0.2%.

  • 3

    Adverse effects were most frequently reported by users of ibogaine and 5-MeO-DMT, with 94.8% and 92.8% respectively experiencing at least one adverse effect.

  • 4

    Worsening physical health was reported by 45.1% of ibogaine users, while 51.2% of psilocybin users reported improved mental health.

  • 5

    The study highlights the need for cautious interpretation of findings due to variations in substance use and potential pharmacological risks.

Original Source(s)

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT

  • by Otto Simonsson, Melissa Bradley, Joshua C. Black, Karilynn M. Rockhill, Andrew A. Monte, Peter S. Hendricks

  • September 29, 2026

Related Content

Academic Stress, Family Relationships, and Social Media Use Disorder Among Turkish Middle School Students: Explanatory Sequential Mixed Methods Study

HHS Awards Almost $250 Million to Expand Addiction Treatment, Overdose Prevention and Mental Health Services

VA/DoD guideline broadens tobacco treatment

Recommendations prioritize varenicline and combination NRT while extending pharmacotherapy to patients not ready to quit.